Clinical Scorecard: Exploring the gut–metabolite–immune interaction: improving the effectiveness and reducing the side effects of immune checkpoint inhibitors
At a Glance
Category
Detail
Condition
Immune checkpoint inhibitors (ICIs)
Key Mechanisms
Gut microbiome composition and microbial metabolites influence ICI efficacy and immune-related adverse events.
Target Population
Patients receiving immune checkpoint inhibitors for malignancies.
Care Setting
Oncological therapeutics
Key Highlights
ICIs disrupt PD-1/PD-L1 and CTLA-4 pathways to enhance antitumor immunity.
Gut microbiota composition is linked to interpatient variability in ICI response.
Specific taxa like Bacteroides, Bifidobacterium, and Akkermansia muciniphila are pivotal for ICI efficacy.
Microbial metabolites can enhance immune cell infiltration and modulate immune responses.
Fecal microbiota transplantation and probiotics show promise in improving ICI outcomes.
Guideline-Based Recommendations
Diagnosis
Assess tumor PD-L1 expression and mutational burden as potential biomarkers for ICI therapy.
Management
Consider microbiome-targeted interventions to enhance ICI efficacy and reduce adverse events.
Monitoring & Follow-up
Monitor for immune-related adverse events associated with ICI therapy.
Risks
Be aware of the potential for interpatient variability in response to ICIs.
Patient & Prescribing Data
Patients with advanced malignancies treated with ICIs.
Microbial interventions may optimize therapeutic responses and mitigate side effects.
Clinical Best Practices
Integrate metagenomics and metabolomics in future studies to understand microbiome interactions.
Conduct large-scale, multicenter studies to validate microbiome-targeted interventions.
